Sponsors & Partners

EUVAS2026 is made possible by the generous support of our sponsors and partners, whose contributions help bring this event to life.

We are proud to showcase these valued partners and extend our sincere thanks for their ongoing support and engagement.

Statement

It is important to note that although this meeting has received sponsorship, by means of financial support, from several organisations, including pharmaceutical companies.

Sponsors have had no involvement in the development of the scientific programme or

agenda, unless explicitly stated.

Thank you to our confirmed sponsors and partners

Headline

CSL is a company focused on iron deficiency and nephrology and is committed to advancing the development of therapies for patients across a range of kidney diseases, with a focus on dialysis and rare diseases. CSL aims to contribute to improving the lives of patients worldwide living with severe and chronic diseases.

Silver

Alentis is a clinical-stage biotechnology company developing first-in-class therapies targeting claudin-1 for a range of fibrosis and oncology indications.


Lixudebart – A pan-organ antifibrotic

The company’s lead claudin-1 targeted antibody, lixudebart (ALE.F02), is designed to reverse fibrosis by selectively targeting exposed caudin-1, which is overexpressed across fibrotic indications and linked to disease progression. Lixudebart demonstrated a favorable safety profile, dose-dependent target engagement and evidence of improved organ function in an ongoing Phase 2 study in ANCA-associated vasculitis with renal involvement (AAV-RPGN) as well as a Phase 1b study in advanced liver fibrosis.

Ongoing Phase 2 in patients with AAV-RPGN - NCT06047171

Otsuka Pharmaceutical Co., Ltd. is a global healthcare company dedicated to enhancing health and wellbeing. Our 35,000 employees worldwide channel their passion into helping advance people’s health through evidence based innovation.

Our wide-ranging business capabilities extend beyond pharmaceuticals, from maintaining everyday health to developing diagnostics and treatments for complex and underserved conditions. In line with our philosophy ‘Otsuka-people creating new products for better health worldwide’, we pursue solutions that address both physical and mental health needs.

In Europe, Otsuka employs around 500 people and focuses on psychiatric and neurologic disorders, nephrology, immunology and haemato-oncology, and digital therapeutics. We have a strong commitment to rare diseases, where unmet needs remain significant. Our work in rare diseases reflects our belief that every patient matters and our dedication to advancing care in areas with limited treatment options.

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach 304 million people worldwide.

At Roche UK, we focus our energy and investment in developing tests and treatments that change lives and give us more quality time with the people we love. And, together with others, we’re aiming to solve healthcare’s greatest challenges; helping to achieve better results by connecting early diagnosis to targeted treatment and ongoing support.

Bronze

Alexion, AstraZeneca Rare Disease, is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and delivery of life-changing medicines. A pioneering leader in rare disease for more than three decades, today it continues to build a diversified pipeline across disease areas with significant unmet need, using an array of innovative modalities.

For more information, please visit: The United Kingdom | Alexion Global Site

NS Pharma is a biopharmaceutical leader in delivering life-changing care to people living with complex, rare diseases. Backed by over 100 years of Nippon Shinyaku Co. development expertise, we advance revolutionary rare disease therapies that help people live healthier, happier lives. Our pipeline includes therapeutic advancements in Duchene muscular dystrophy, MPS II, EGPA and LCA1. By uniting strategic partnerships, novel scientific innovation and expansive organizational expertise, we consistently drive meaningful therapeutic progress that addresses unmet needs and supports the full patient journey. Our award-winning patient services illustrate our promise to provide dedicated partnership for the unique needs of every patient.

Support Partners

The aims of Vasculitis UK are:

  • To support those suffering from vasculitis diseases and their families by providing information and advice.
  • To inform and educate those with vasculitis about their illness so that they are empowered to take greater control of it.
  • To work with other organisations and medical professionals to improve the recognition, diagnosis and treatment of vasculitis diseases.
  • To raise awareness of vasculitis disease among medical professionals and the general population.
  • To enable vasculitis sufferers to contact others with vasculitis.
  • To encourage and support the formation and development of local vasculitis support groups.
  • To support high‑quality research that deepens understanding of the causes of vasculitis, advances earlier and more accurate diagnosis, and drives the development of safer, more effective treatments and real‑world interventions that improve the long‑term outcomes and quality of life of people living with all types of vasculitis.

ERN-RITA is a network (representing and) connecting physicians, researchers, patients and patient representatives for rare immunological disorders, including primary immunodeficiency, autoimmune, autoinflammatory and paediatric rheumatic disorders across Europe. It provides a platform for exchange (sharing) of knowledge and expertise, collaboration, and partnership in transdisciplinary projects to promote education and research integrating (involving) all RITA immune disciplines (fields, streams).


ERN-RITA working groups conduct a range of activities to ensure equal access to early diagnosis, to foster best practice management, to advance standards of clinical care for all patients with rare immunological disorders across Europe, regardless of nationality or residence. To achieve these goals, ERN-RITA is strongly connected to European scientific societies, including those for Immunodeficiencies (ESID), Autoimmune Vasculitis (EUVAS), Autoinflammatory Diseases (ISSAID) and Pediatric Rheumatology (PReS) as well as patient organisations.

Bronze